| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2015-10-30 |
| タイトル |
|
|
タイトル |
Current therapeutic strategies for multiple myeloma. |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Multiple myeloma |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Autologous stem cell transplantation |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Immunomodulatory agents |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Proteasome inhibitors |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Histone deacetylase inhibitors |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
鳥本, 悦宏
進藤, 基博
生田, 克哉
高後, 裕
|
| 著者 ローマ字 |
|
|
|
Torimoto, Yoshihiro |
| 著者 ローマ字 |
|
|
|
Shindo, Motohiro |
| 著者 ローマ字 |
|
|
|
Ikuta, Katsuya |
| 著者 ローマ字 |
|
|
|
Kohgo, Yutaka |
| 書誌情報 |
International journal of clinical oncology.
巻 20,
号 3,
p. 423-430,
発行日 2015-06-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1341-9625 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s10147-015-0826-3. |
| リンクURL |
|
|
内容記述タイプ |
Other |
|
内容記述 |
http://link.springer.com/article/10.1007%2Fs10147-015-0826-3 | http://link.springer.com/article/10.1007%2Fs10147-015-0826-3 |
| 識別番号 その他 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
PMID:25855312 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The introduction of novel molecular targeting agents against multiple myeloma has dramatically and rapidly changed the therapeutic strategies for this incurable hematologic disease. Novel agents such as thalidomide, bortezomib and lenalidomide have significantly improved the response rate, progression-free survival, and overall survival compared with conventional chemotherapies, and made it easy to control the disease for longer periods of time. Initial therapies for newly diagnosed myeloma patients depend on the individual's clinical condition. Induction therapy with novel agents and high-dose chemotherapy followed by autologous stem cell transplantation is a standard therapy for newly diagnosed younger myeloma patients. On the other hand, several combinations of novel agents and other drugs (melphalan, prednisone, dexamethasone, etc.) are widely used as initial therapy for transplantation-ineligible myeloma patients. Although the clinical advantage of maintenance therapy after induction therapy has been reported, it is not recommend in routine practice. Maintenance therapy would be an option for some patients. Despite the significant improvements with the use of novel agents, the majority of patients eventually relapse. A number of treatment options including novel agents, which demonstrated marked clinical effects, are reported in the setting of salvage therapy. The choice of appropriate therapy for relapsed or refractory patients must take the disease status or patient status in consideration. Furthermore, a new generation of novel agents such as pomalidomide, carfilzomib or panobinostat has recently become available for relapsed or refractory myeloma. It is necessary to determine the optimal combination of drugs, administration timing and patients to be treated in future clinical trials. |
| 資源タイプ |
|
|
内容記述タイプ |
Other |
|
資源タイプ |
text |
| 著者版フラグ |
|
|
出版タイプ |
AM |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| ID(XooNIps) |
|
|
|
25855312 |
| 閲覧数(XooNIps) |
|
| ダウンロード数(XooNIps) |
|
|
|
518 |
6237.pdf (276.7 kB)
